NCT06059547View on ClinicalTrials.gov

Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

September 6, 2023

Primary Completion Date

August 30, 2025

Study Completion Date

September 30, 2026

Conditions
Bladder CancerAdult Solid Tumor
Interventions
DRUG

Nivolumab

Biological, monoclonal antibody

DRUG

Visugromab (CTL-002)

Biological, monoclonal antibody

DRUG

Placebo

Placebo (NaCl) for Visugromab (CTL-002)

Trial Locations (4)

10126

A.O.U. Città della Salute e della Scienza di Torino, Torino

20132

IRCCS Ospedale San Raffaele Hospital Vita-Salute San Raffaele University, Milan

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

00168

Fondazione Policlinico Universitario Agostino Gemelli IRCCS, UOC Oncologia Medica, Roma

All Listed Sponsors
lead

CatalYm GmbH

INDUSTRY

NCT06059547 - Neoadjuvant Immunotherapy Combined With the Anti-GDF-15 Antibody Visugromab to Treat Muscle Invasive Bladder Cancer | Biotech Hunter | Biotech Hunter